For years, diagnosing Alzheimer’s disease has often meant a long road.
Memory tests. Brain scans. Specialist visits. Sometimes a spinal tap.
Now, that future may be changing.
In May 2025, the U.S. Food and Drug Administration cleared the first blood test used to help diagnose Alzheimer’s disease. The test, called Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, is designed for adults 55 and older who already have signs or symptoms of cognitive decline. It measures two blood-based proteins linked to amyloid plaques in the brain, one of the biological signs associated with Alzheimer’s disease.
FDA approves first blood test to help screen for Alzheimer’s disease
That sounds simple.
But the important detail is this: it is not meant to be a casual screening test for healthy people.
The FDA says the test is intended to help detect amyloid plaques in people who are already showing symptoms. It must also be interpreted alongside other clinical information, not used alone as a final diagnosis.
That is where the story becomes more interesting.
Because the future of Alzheimer’s care may not be about one miracle test. It may be about building a faster, cheaper, more accessible diagnostic pathway.
Right now, amyloid plaques are often checked using amyloid PET scans or cerebrospinal fluid testing. PET scans can be expensive and time-consuming. Spinal fluid testing requires a lumbar puncture. A blood test could reduce reliance on those methods and make the first stage of diagnosis easier for many patients.
The numbers are promising.
In the FDA-reviewed study of 499 cognitively impaired adults, 91.7% of people with a positive Lumipulse result also had amyloid plaques confirmed by PET scan or CSF testing. Among people with a negative result, 97.3% also had a negative amyloid PET or CSF result.
That does not mean the test is perfect.
The FDA warns that false positives and false negatives are possible. A false positive could lead to distress, unnecessary treatment, extra cost, or delayed diagnosis of the real cause of symptoms. A false negative could delay proper Alzheimer’s evaluation.
That caution is also reflected in the Alzheimer’s Association’s 2025 clinical practice guideline.
The guideline says blood-based biomarker tests can help in specialized memory-care settings for people with objective cognitive impairment, but they should not be ordered before a full clinical evaluation. The results should always be interpreted in the patient’s clinical context.
The guideline also makes a key distinction.
Blood tests with high sensitivity may be useful as a triage tool, especially when a negative result helps rule out Alzheimer’s pathology. But positive results may still need confirmation with another method, such as CSF testing or amyloid PET imaging. Blood tests with both high sensitivity and high specificity may eventually substitute for some PET or CSF testing in the right setting.
That could be a major future shift.
A 2024 JAMA study found that one blood-based Alzheimer’s test approach had high diagnostic accuracy in people with cognitive symptoms. In that study, the test showed about 88% to 92% accuracy for detecting Alzheimer’s disease pathology in primary and secondary care. The same paper reported that primary care physicians had 61% diagnostic accuracy, while dementia specialists had 73%, compared with 91% using the blood test approach.
That is why this topic matters.
If blood tests become reliable, widely available, and properly regulated, Alzheimer’s diagnosis could move earlier in the patient journey. People with symptoms may be referred faster. Specialists may be able to prioritize higher-risk cases. Families may get clearer answers sooner. And patients being considered for newer Alzheimer’s treatments may be evaluated more efficiently.
But there is a danger in overselling it.
Mayo Clinic explains that these tests should be used clinically in people who show symptoms, not as general screening for people with no symptoms. It also notes that Lumipulse cannot diagnose Alzheimer’s disease on its own and should be part of a broader evaluation that may include history, physical exam, cognitive testing, and imaging.
That makes the future question bigger than one FDA clearance.
Will blood tests make dementia diagnosis more equal and accessible?
Or will they create new problems, such as overtesting, anxiety, misinterpretation, insurance gaps, and confusion over what a positive result really means?
The responsible answer is somewhere in the middle.
Alzheimer’s blood tests may become one of the most important diagnostic tools of the next decade. But the safest future is not a world where anyone orders a test online and panics over the result.
It is a world where blood tests are used carefully, by trained clinicians, for the right patients, at the right time.
That may not sound as flashy as a miracle cure.
But for families facing memory loss, a faster and more accurate path to answers could still be a major medical turning point.
References
- FDA — FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease
- Alzheimer’s Association — Clinical Practice Guideline for Blood-Based Biomarker Tests
- JAMA — Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
- Mayo Clinic — New FDA-approved blood tests for diagnosing Alzheimer’s disease